Quantitative high-throughput screen identifies inhibitors of the Schistosoma mansoni redox cascade

PLoS Neglected Tropical Diseases

Volumn 2, Issue 1, 2008, Pages

  Simeonov, Anton ^a   Jadhav, Ajit ^a   Sayed, Ahmed A ^b   Wang, Yuhong ^a   Nelson, Michael E ^a   Thomas, Craig J ^a   Inglese, James ^a   Williams, David L ^b   Austin, Christopher P ^a  

^a NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^b ILLINOIS STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTISCHISTOSOMAL AGENT; ANTITREMATODAL AGENT; GLUTATHIONE; HYDROGEN PEROXIDE; ISOXAZOLONE DERIVATIVE; NATURAL PRODUCT; OXADIAZOLE 2 OXIDE DERIVATIVE; PEROXIREDOXIN; PHOSPHINIC AMIDE DERIVATIVE; PHOSPHORAMIDOUS ACID DERIVATIVE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; SULFONAMIDE; THIOREDOXIN REDUCTASE; ENZYME INHIBITOR; MULTIENZYME COMPLEX; N NITROSOALLYL 2,3 DIHYDROXYPROPYLAMINE; N-NITROSOALLYL-2,3-DIHYDROXYPROPYLAMINE; NITROSAMINE; OXIDOREDUCTASE; THIOREDOXIN GLUTATHIONE REDUCTASE;

ARTICLE; AUTOFLUORESCENCE; CATALYSIS; CONTROLLED STUDY; DRUG IDENTIFICATION; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME INHIBITION; HIGH THROUGHPUT SCREENING; IC 50; NONHUMAN; OXIDATION REDUCTION STATE; QUANTITATIVE ANALYSIS; SCHISTOSOMA MANSONI; STRUCTURE ACTIVITY RELATION; ANIMAL; DRUG ANTAGONISM; DRUG EFFECT; ENZYMOLOGY; HUMAN; METABOLISM; OXIDATION REDUCTION REACTION; PATHOPHYSIOLOGY; PHYSIOLOGY; SCHISTOSOMIASIS MANSONI;

ANIMALS; DRUG EVALUATION, PRECLINICAL; ENZYME INHIBITORS; HUMANS; HYDROGEN PEROXIDE; MULTIENZYME COMPLEXES; NADH, NADPH OXIDOREDUCTASES; NITROSAMINES; OXIDATION-REDUCTION; PEROXIREDOXINS; SCHISTOSOMA MANSONI; SCHISTOSOMIASIS MANSONI;

EID: 48949117601     PISSN: None     EISSN: None     Source Type: Journal    
DOI: 10.1371/journal.pntd.0000127     Document Type: Article

References (40)

1. WHO (2006) Report of the Scientific Working Group on Schistosomiasis, 2005. Geneva: TDR/World Health Organization. 123 p.
2. King CH, Dickman K, Tisch DJ (2005) Reassesment of the cost of chronic helmintic infection: a meta-analysis of disability-related outcomes in endemic schistosomiasis. [see comment]. Lancet 365: 1561-1569.
3. van der Werf MJ, de Vlas SJ, Brooker S, Looman CW, Nagelkerke NJ, et al. (2003) Quantification of clinical morbidity associated with schistosome infection in sub-Saharan Africa. Acta Tropica 86: 125-139.
4. Vermund SH, Bradley DJ, Ruiz-Tiben E (1983) Survival of Schistosoma mansoni in the human host: estimates from a community-based prospective study in Puato Rico. Am J Trop Med Hyg 32: 1040-1048.
5. Cioli D, Pica-Mattoccia L (2003) Praziquantel. Parasitol Res 90 Supp, 1: S3-9.
6. Doenhoff M, Kimani G, Cioli D (2000) Praziquantel and the control of schistosomiasis. Parasitol Today 16: 364-366.
7. Jeziorski MC, Greenberg RM (2006) Voltage-gated calcium channel subunits from platyhelminths: potential role in praziquantel action. Int J Parasitol 36: 625-632.
8. Pica-Mattoccia L, Valle C, Basso A, Troiani AR, Viprosi F, et al. (2007) Cytochalasin D abolishes the schistosomicidal activity of praziquantel. Exp Parasitol 115: 344-351.
9. Fallon PG, Doenholf MJ (1994) Drug-resistant schistosomiasis: resistance to praziquantel and oxamniquine induced in Schistosoma mansoni in mice is drug specific. Am J Tropical Med & Hyg 51: 83-88.
10. Cioli D, Pica-Mattoccia L, Archer S (1995) Antischistosomal drugs: past, present and future? Pharmacol Therapeutics 68: 35-85.
11. Fallon PG, Sturrock RF, Niang AC, Doenhoff MJ (1995) Short report: diminished susceptibility to praziquantel in a Senegal isolate of Schistosoma mansoni Am J Trop Med & Hyg 53:61-62
12. Utzinger J, Xiao SH, Tanner M, Keiser J (2007) Artemisinins for schistosomiasis and beyond. Curr Op Inv Drugs 8: 105-116.
13. Xiao S-H, Keiser J, Chollet J, Utzinger J, Dong Y, et al. (2007) In Vitro and In Vivo Activities of Synthetic Trioxolanes against Major Human Schistosome Species. Antimicrob Agents Chemother 51: 1440-1445.
14. Mkoji GM, Smith JM, Prichard RK (1988) Antioxidant systems in Schistosoma mansoni: correlation between susceptibility to oxidant killing and the levels of scavengers of hydrogen peroxide and oxygen free radicals. Int J Parasitol 18: 661-666.
15. Alger HM, Williams DL (2002) The disulfide redox system of Schistosoma mansoni and the importance of a multifunctional enzyme, thioredoxin glutathione reductase. Mol Biochem Parasitol 121: 129-139.
16. Salinas G, Selkirk ME, Chalar C, Maizels RM, Fernandez C (2004) Linked thioredoxin-glutathione systems in platyhelminths. Trends Parasitol 20: 340-346.
17. Kuntz AN, Davioud-Charvet E, Sayed AA, Califf LL, Dessolin J, et al. (2007) Thioredoxin Glutathione Reductase from Schistosoma mansoni: An Essential Parasite Enzyme and a Key Drug Target. PLoS Med 4: 1071-1086.
18. Sayed AA, Williams DL (2004) Biochemical characterization of 2-Cys peroxiredoxins from Schistosoma mansoni. J Biol Chem 279: 26159-26166.
19. Hopkins AL, Witty MJ, Nwaka S (2007) Mission possible. Nature 449: 166.
20. Butler D (2007) Lost in translation. Nature 449: 158.
21. Austin CP, Brady LS, Insel TR, Collins FS (2004) NIH Molecular Libraries Initiative. Science 306: 1138-1139.
22. Sayed AA, Cook SK, Williams DL (2006) Redox balance mechanism in Schistosoma mansoni rely on peroxiredoxins and albumin and implicate peroxiredoxins as novel drug targets. J Biol Chem 281: 17001-17010.
23. Inglese J, Johnson RL, Simeonov A, Xia M, Zheng W, et al. (2007) High-throughput screening assays for the identification of chemical probes. Nat Chem Biol 3: 466-479.
24. Luthman M, Hohngren A (1982) Rat liver thioredoxin and thioredoxin reductase: purification and characterization. Biochemistry 21: 6628-6633.
25. Inglese J, Auld DS, Jadhav A, Johnson RL, Simeonov A, et al. (2006) Quantitative high-throughput screening: a titration-based approach that efficiently identifies biological activities in large chemical libraries. Proc Nat Acad Sci USA 103: 11473-11478.
26. Hill AV (1910) The Possible Effects of the Aggregation of the Molecule of Harmoglobin on its Dissociation Curves. J Physiol (London) 40: 4-7.
27. Roberts G, Myatt GJ, Cross KP, Blower PEJ (2000) LeadScope: Software for Exploring Large Sets of Screening Data. J Chem Inf Comput Sci 40: 1302-1314.
28. Niles WD, Coassin PJ (2005) Piezo- and Solenoid Valve-Based Liquid Dispensing for Miniaturized Assays. Assay Drug Devel Technol 3: 189-202.
29. Holmgren A, Bjornstedt M (1995) Thioredoxin and thioredoxin reductase. Meth Enzymol 252: 199-208.
30. Zhang JH, Chung TD, Oldenburg KR (1999) A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays. J Biomol Screen 4: 67-73.
31. Eastwood BJ, Farmen MW, Iversen PW, Craft TJ, Smallwood JK, et al. (2006) The Minimum Significant Ratio: A Statistical Parameter to Characterize the Reproducibility of Potency Estimates from Concentration-Response Assays and Estimation by Replicate-Experiment Studies. J Biomol Screen 11: 253-261.
32. Imbert P-E, Unterreiner V, Siebert D, Gubler H, Parker, C, et al. (2007) Recommendations for the Reduction of Compound Artifacts in Time-Resolved fluorescence Resonance Energy Transfer Assays. Assay Drug Dev Technol 5: 363-372.
33. Iyer R, Barrese AA 3rd, Parakh S, Parker CN, Tripp BC (2006) Inhibition profiling of human carbonic anhydrase II by high-throughput screening of structurally diverse, biologically active compounds. J Biomol Screen 11: 782-791.
34. Feng BY, Shelat A, Doman TN, Guy RK, Shoichet BK (2005) High-throughput assays for promiscuous inhibitors. Nat Chem Biol 1: 146-148.
35. Feng BY, Simeonov A, Jadhav A, Babaoglu K, Inglese J, et al. (2007) A high-throughput screen for aggregation-based inhibition in a large compound library. J Med Chem 50: 2385-2390.
36. Gromer S, Arscott LD, Williams CH Jr, Schirmer RH, Becker K (1998) Human placenta thioredoxin reductase. Isolation of the selenoenzyme, steady state kinetics, and inhibition by therapeutic gold compounds. J Biol Chem 273: 20096-20101.
37. Harder A (2002) Chemotherapeutic approaches to schistosomes: current knowledge and outlook. Parasitol Res 88: 395-397.
38. Lu J, Chew E-H, Holmgren A (2007) Targeting Thiordoxin Reductase is a Basis for Cancer Therapy by Arsenic Trioxide. Proc Nat Acad Sci USA 104: 12288-12293.
39. Cerecetto H, Porcal W (2005) Pharmacological properties of furoxans and benzofuxroxans: recent developments. Mini-Rev Med Chem 5: 57-71.
40. Medana C, Ermondi G, Fruttero R, Di Stilo A, Ferretti C, et al. (1994) Furoxans as nitric oxide donors. 4-Phenyl-3-furoxancarbonitrile: thiol-mediated nitric oxide release and biological evaluation. J Med Chem 37: 4412-4416.